Viscoelasticity

IDTechEx Explores Technology Trends in Dielectric Materials for Next Generation 2.5D and 3D Semiconductor Packaging

Retrieved on: 
Wednesday, March 27, 2024
Temperature, Communication, Silicon dioxide, L/S, Polymer, Copper, CTE, Coefficient, CMP, TCB, Intermetallic, RDL, Miniaturization, Ecosystem, Young, Viscoelasticity, IMC, Printed circuit board

This article explores the technology trends in dielectric materials for both 2.5D and 3D packaging, with insights drawn from IDTechEx's market report on the topic, " Materials and Processing for Advanced Semiconductor Packaging 2024-2034 ".

Key Points: 
  • This article explores the technology trends in dielectric materials for both 2.5D and 3D packaging, with insights drawn from IDTechEx's market report on the topic, " Materials and Processing for Advanced Semiconductor Packaging 2024-2034 ".
  • However, traditional inorganic dielectric materials like SiO2, though capable of achieving fine L/S, suffer from high dielectric constants (Dk=3.9) and are tied to the Si manufacturing technique.
  • Organic dielectric materials emerge as promising alternatives for advanced semiconductor packaging, offering lower dielectric constants and cost advantages.
  • Finally, the report includes a 10-year market forecast for Organic Dielectric Advanced Semiconductor Packaging, providing industry perspectives on market growth and trends.

IDTechEx Explores Technology Trends in Dielectric Materials for Next Generation 2.5D and 3D Semiconductor Packaging

Retrieved on: 
Wednesday, March 27, 2024
Temperature, Communication, Silicon dioxide, L/S, Polymer, Copper, CTE, Coefficient, CMP, TCB, Intermetallic, RDL, Miniaturization, Ecosystem, Young, Viscoelasticity, IMC, Printed circuit board

This article explores the technology trends in dielectric materials for both 2.5D and 3D packaging, with insights drawn from IDTechEx's market report on the topic, " Materials and Processing for Advanced Semiconductor Packaging 2024-2034 ".

Key Points: 
  • This article explores the technology trends in dielectric materials for both 2.5D and 3D packaging, with insights drawn from IDTechEx's market report on the topic, " Materials and Processing for Advanced Semiconductor Packaging 2024-2034 ".
  • However, traditional inorganic dielectric materials like SiO2, though capable of achieving fine L/S, suffer from high dielectric constants (Dk=3.9) and are tied to the Si manufacturing technique.
  • Organic dielectric materials emerge as promising alternatives for advanced semiconductor packaging, offering lower dielectric constants and cost advantages.
  • Finally, the report includes a 10-year market forecast for Organic Dielectric Advanced Semiconductor Packaging, providing industry perspectives on market growth and trends.

Clinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion Diagnostics

Retrieved on: 
Thursday, December 15, 2022
Patient, CBC, South London and Maudsley NHS Foundation Trust, Research, Viscoelasticity, FDA, Psychiatry, Quality of life, Journal, Nathan Kline Institute for Psychiatric Research, WBC, Schizophrenia, Complete blood count, Journal of Psychiatric Research, National Association Medical Staff Services, Medical device, Clozapine

Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.

Key Points: 
  • Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.
  • The clinical evaluation comprising 226 Clozapine-treated patients has found strong correlations between the standard lab venous method and HemoScreen's capillary and venous assays.
  • This study, which is being published in the Journal of Psychiatric Research, concluded HemoScreen to be a viable fit for finger-prick companion diagnostics, with the potential to substantially enhance treatment enrollment and adherence.
  • "HemoScreen offers a portable, quick and accurate alternative to the current venous blood non-portable methods of clozapine monitoring, and from a single drop of either capillary or venous blood.

New Age for Point-of-Care Diagnostics: PixCell Medical's HemoScreen Surpasses Leading Lab Hematology Analyzer Sysmex XN in Flagging of Abnormal WBC

Retrieved on: 
Wednesday, November 16, 2022
Quality of life, Sysmex Corporation, WBC, Complete blood count, CBC, University, FDA, University of Turku, Red blood cell, Viscoelasticity, Solution, Medical device, Hematology

This ground-breaking study showed HemoScreen to be more accurate in regard to leukocyte abnormalities (flagging all abnormalities).

Key Points: 
  • This ground-breaking study showed HemoScreen to be more accurate in regard to leukocyte abnormalities (flagging all abnormalities).
  • It demonstrated better specificity (88% versus Sysmex XN's 72%) as it was less prone to false flagging versus the Sysmex XN, this is owing to HemoScreen's novel machine learning-driven viscoelastic focusing technology.
  • "HemoScreen hematology analyzer is essentially comparable to Sysmex XN for CBC and WBC differential analysis.
  • HemoScreen was less prone to false WBC flagging compared to Sysmex XN, thereafter requiring less microscopy review.

PixCell Medical Partners with Insight Medical to Distribute the Hematology Point-of-Care Analyzer HemoScreen™ in Papua New Guinea

Retrieved on: 
Tuesday, September 6, 2022
PNG, Partnership, CEO, Complete blood count, Solution, Hematology, Laboratory, Quality of life, Prevalence, Viscoelasticity, FDA, CBC, Canine vector-borne disease, Medical device, Malaria

YOKNEAM ILLIT, Israel, Sept. 6, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced a partnership with Insight Medical, a medical supply and service company based in Port Moresby, Papua New Guinea.

Key Points: 
  • YOKNEAM ILLIT, Israel, Sept. 6, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced a partnership with Insight Medical, a medical supply and service company based in Port Moresby, Papua New Guinea.
  • Insight Medical will serve as the exclusive distributor of PixCell's HemoScreen, a hematology analyzer designed for use at the point of care, across Papua New Guinea.
  • Insight Medical's mission is to enhancing the healthcare quality available in Papua New Guinea, with a commitment to providing quality health care access, including modern medical equipment and specialist care.
  • Currently, most of Papua New Guinea's 9 million citizens live in rural communities, facing many healthcare and infrastructure challenges.

PixCell Medical Names Mark Erez as Chief Financial Officer

Retrieved on: 
Wednesday, June 8, 2022
CFO, Bar-Ilan University, CEO, Complete blood count, Viscoelasticity, Solution, University, FDA, Growth, PWC, Protalix BioTherapeutics, University of Haifa, Economics, Quality of life, Erez, Strategic planning, CBC, Management

YOKNEAM ILLIT, Israel , June 8, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, announced today that Mr. Mark Erez has been appointed the company's new Chief Financial Officer (CFO). Erez will oversee financial planning in support of PixCell's continued commercial expansion across the globe.

Key Points: 
  • YOKNEAM ILLIT, Israel, June 8, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, announced today that Mr. Mark Erez has been appointed the company's new Chief Financial Officer (CFO).
  • Erez will oversee financial planning in support of PixCell's continued commercial expansion across the globe.
  • Mark Erez joins PixCell with two decades of significant experience as a financial executive.
  • "Following a rigorous search process, we are thrilled to welcome Erez onboard our growing team," stated Avishay Bransky, Ph.D., co-founder and CEO of PixCell Medical.

PixCell Medical Appoints Ryan Venturi as General Manager of Newly Opened U.S. Office

Retrieved on: 
Monday, April 25, 2022
CEO, Calibration, Adoption, Complete blood count, CBC, VP, Viscoelasticity, Infection, Blood, RPM, Health, Solution, Maintenance, Abbott, FDA, Quality of life, Venturi, Pharmaceutical industry, Medical device

YOKNEAM ILLIT, Israel, April 25, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, announced today that Ryan Venturi has been appointed general manager of the company's U.S. subsidiary office. Venturi will help drive PixCell's commercial expansion and distribution of the company's award-winning hematology analyzer, HemoScreen™, in the Americas.

Key Points: 
  • YOKNEAM ILLIT, Israel, April 25, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, announced today that Ryan Venturi has been appointed general manager of the company's U.S. subsidiary office.
  • Venturi will help drive PixCell's commercial expansion and distribution of the company's award-winning hematology analyzer, HemoScreen, in the Americas.
  • He previously served as VP of Sales at Coag-Sense and as National Sales Director for Alere, acquired by Abbott.
  • "As general manager of PixCell's U.S. branch, I look forward to facilitating the increased adoption of PixCell's HemoScreen across American markets."

PixCell's HemoScreen™ Takes Home Gold and Best-in-Show Awards in 2022 Medical Design Excellence Competition

Retrieved on: 
Tuesday, April 12, 2022
CBC, Method, Medicine, Lymphatic system, Viscoelasticity, City centre, AI, System, CEO, Gold, Anemia, Quality of life, Health, POC, Technology, MDEA, Machine learning, Solution, Complete blood count, Disease management, FDA, Blood, Engineering, Patient, Infection, Pharmaceutical industry, Medical device

YOKNEAM ILLIT, Israel, April 12, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced that HemoScreen™ was named a gold winner in the Testing and Diagnostic Products and Systems category in the 2022 Medical Design Excellence Awards (MDEA). In addition, HemoScreen™ was named the Best-in-Show winner, MDEA's top honor.

Key Points: 
  • YOKNEAM ILLIT,Israel, April 12, 2022 /PRNewswire/ -- PixCell Medical ,innovator of rapid hematology testing solutions at the point-of-care,today announced that HemoScreen was named a gold winner in the Testing and Diagnostic Products and Systems category in the 2022 Medical Design Excellence Awards (MDEA) .
  • MDEA, the medtech industry's premier awards program, honors significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
  • "This could have a positive impact on time-to-rescue considering quicker differential diagnosis can lead to quicker interventions.
  • The cost point compared to return-on-investment is attractive given the frequency of use and ability for those without med tech qualifications to process."

Katalyst Diagnostics Becomes Sole Distributor of PixCell Medical's HemoScreen™ in the UK and Ireland

Retrieved on: 
Tuesday, March 8, 2022
Diagnosis, POC, United Kingdom, Infection, Adoption, Point-of-care testing, Quality of life, Public health, Calibration, Complete blood count, Blood, Katalyst, FDA, Solution, Soho Square, Viscoelasticity, Health, Decision-making, Marketing, Maintenance, CEO, CBC, AI, Partnership, COVID-19, PCR, Medical device

YOKNEAM ILLIT, Israel, March 8, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced that it has signed an exclusive distribution agreement with Katalyst Diagnostics, a new division of Katalyst Laboratories, to distribute HemoScreen™ across the United Kingdom and Ireland. HemoScreen is the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care (POC) use.

Key Points: 
  • HemoScreen is the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care (POC) use.
  • As part of the growing need for quality POC diagnostics, the company formed a new division, Katalyst Diagnostics, to distribute AI technologies and solutions across the region.
  • "We are thrilled to partnerwith a 'boots-on-the-ground' company like Katalyst Diagnostics, working diligently to alleviate the impact of the pandemic on public health in the UK and Ireland.
  • Forming part of the Katalyst group, Katalyst Diagnostics is a highly specialised diagnostics partner dedicated to sourcing next-generation, cutting-edge diagnostic solutions from across the world, aimed at improving healthcare outcomes.

PixCell Medical Awarded Grant by International Health-Tech Pilot Program

Retrieved on: 
Tuesday, February 22, 2022
Partnership, Microfluidics, Berlin Institute for Population and Development, Israel Innovation Authority, International, CBC, Viscoelasticity, Complete blood count, Machine learning, FDA, National Association Medical Staff Services, Blood, BIH, Quality of life, Technology, AI, IIA, Solution, CEO, Program, Department, Pharmaceutical industry, Medical device

YOKNEAM ILLIT, Israel, Feb. 22, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced that it has been awarded a grant by the International Health-Tech Pilot Program .

Key Points: 
  • YOKNEAM ILLIT, Israel, Feb. 22, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced that it has been awarded a grant by the International Health-Tech Pilot Program .
  • The program aims to increase the availability of new medical technologies, improving global patient care through international collaboration.
  • PixCell Medical provides healthcare systems with the only 5-part CBC solution that is FDA-cleared for point-of-care use - the HemoScreen.
  • With over 70 companies vying for the grant during the first round of proposals, Pixcell Medical was one of just four Israeli start-ups to receive funding.